Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect

(2014) Nirav Dhanesha et al.   Pharmacological Reports

A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor

(2014) Lucy S. Jun et al.   PLoS One

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice

(2013) B. A. Omar et al.   DIABETES

Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model

(2013) P. Richards et al.   DIABETES

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency

(2013) H. E. Wilson-Perez et al.   DIABETES

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges

(2013) Tara Ghazi et al.   DIABETES CARE

Glucagon-Like Peptide-1 Protects Human Islets against Cytokine-Mediated β-Cell Dysfunction and Death: A Proteomic Study of the Pathways Involved

(2013) Dieter Rondas et al.   JOURNAL OF PROTEOME RESEARCH

Liver-Specific Disruption of the Murine Glucagon Receptor Produces  -Cell Hyperplasia: Evidence for a Circulating  -Cell Growth Factor

(2012) C. Longuet et al.   DIABETES

Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

(2012) A. M. Arafat et al.   DIABETOLOGIA

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

(2012) Roger H. Unger et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic manifestations of insulin deficiency do not occur without glucagon action

(2012) Y. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice

(2011) Melissa A. Burmeister et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice

(2011) Y. Lee et al.   DIABETES

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES CARE

Liraglutide as additional treatment for type 1 diabetes

(2011) Ajay Varanasi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible  -Cell Hyperplasia and Hyperglucagonemia

(2009) W. Gu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

(2008) Julio E. Ayala et al.   ENDOCRINOLOGY